ImmuneOncia Therapeutics

이뮨온시아 · 424870

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$283.2M (₩390.8B)

Overview

ImmuneOncia Therapeutics develops antibody-based cancer immunotherapy drugs, medicines that help the immune system recognize and attack tumors.

It holds a pipeline of monoclonal antibodies (highly targeted proteins engineered to block specific cancer-promoting signals) as its core assets. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company operates primarily as a drug-licensing business: it advances candidate therapies through early clinical trials, then transfers the technology to partners in exchange for licensing fees, while also pursuing domestic commercialization of its lead antibody.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$80.6K
Operating profit · FY2025
−US$20.3M
Net income · FY2025
−US$19.8M

Revenue

  • FY2025US$80.6K

Operating profit

  • FY2025−US$20.3M

Net income

  • FY2025−US$19.8M

Key ratios (FY2025)

ROE
-96.3%
Debt/Eq
16.6%
Op. margin
-25182.0%
Net margin
-24605.1%
Rev. YoY
N/A (see filing)

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.